Randomised, Double-Blind, Controlled Phase I Trial of the Safety, Tolerability and Immunogenicity of Graded Doses of STX-100/Alhydrogel, a Recombinant Enterovirus A 71 (EV-A71) Virus-Like Particle Vaccine in Healthy Adults
Phase of Trial: Phase I
Latest Information Update: 24 Jan 2018
At a glance
- Drugs STX 100/Alhydrogel (Primary)
- Indications Enterovirus A infections
- Focus Adverse reactions; First in man
- Sponsors Sentinext Therapeutics
- 15 Jan 2018 Planned End Date changed from 5 Feb 2018 to 2 Aug 2018.
- 15 Jan 2018 Planned initiation date changed from 18 Jul 2017 to 18 Jan 2018.
- 15 Jan 2018 Status changed from not yet recruiting to recruiting.